Group 1 - The core point of the article is that Ibuprofen granules have been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024 Edition) as a Class B product, indicating strong demand and clinical application for this common analgesic and antipyretic drug [1] - Ibuprofen is effective in alleviating mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, and is also suitable for fever caused by common colds or influenza [1] - Xinhua Pharmaceutical, as a leading enterprise in the integrated production of ibuprofen raw materials and formulations in China, has established a complete ibuprofen industry chain from pharmaceutical intermediates to raw materials and formulations [1] Group 2 - The company has developed a diverse range of ibuprofen products, including ibuprofen tablets, ibuprofen pseudoephedrine tablets, ibuprofen suspension, ibuprofen sustained-release capsules, ibuprofen suspension drops, and the newly approved ibuprofen granules, catering to various clinical medication needs [1] - The company relies on a self-controlled raw material supply system, a strict and standardized quality management system, and continuous R&D innovation capabilities to enhance its ibuprofen product matrix [1] - Recently, Xinhua Pharmaceutical's subsidiary, Xinda Pharmaceutical, received approval from the National Medical Products Administration for the market launch of ibuprofen granules [2]

Group 1 - The core point of the article is that Xinhua Pharmaceutical has received approval for its Ibuprofen granules from the National Medical Products Administration [2] Group 2 - The approval was granted to Shandong Zibo Xinda Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Xinhua Pharmaceutical [2] - The issuance of the drug registration certificate marks a significant milestone for the company in expanding its product offerings [2]

Core Viewpoint - Xinhua Pharmaceutical announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., received the drug registration certificate for ibuprofen granules from the National Medical Products Administration, indicating a significant regulatory approval for a product aimed at pain relief and fever reduction [1] Company Summary - The approved ibuprofen granules are intended for alleviating mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea [1] - The product can also be used to reduce fever caused by common colds or influenza [1]

Group 1 - Core viewpoint: Xinhua Pharmaceutical (SZ 000756) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Ibuprofen Granules from the National Medical Products Administration [1] Group 2 - Company announcement: The announcement was made on the evening of March 23, with the closing price of Xinhua Pharmaceutical at 13.96 yuan [1]

Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for its ibuprofen granules, which are intended to relieve mild to moderate pain and fever associated with common colds and influenza [1] - The ibuprofen granules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 edition) [1] - The sales revenue for ibuprofen-related formulations in Chinese public medical institutions is projected to be approximately RMB 4.4 billion in 2024 [1] Group 2 - The approval of this product enhances the variety of ibuprofen formulations offered by the company, providing more medication options for patients [1]

Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for ibuprofen granules from the National Medical Products Administration [1] Group 2 - The approval of the ibuprofen granules indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio and market competitiveness [1] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical market [1] - The registration of ibuprofen granules aligns with the company's strategy to innovate and diversify its pharmaceutical products [1]

Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Ibuprofen granules from the National Medical Products Administration [1] Group 2 - The approval of the Ibuprofen granules registration certificate signifies a potential expansion in the company's product offerings [1] - This development may enhance the company's market position in the pharmaceutical industry, particularly in the analgesic segment [1] - The registration could lead to increased revenue opportunities for the company as it introduces the new product to the market [1]

Core Viewpoint - The announcement indicates that the company's subsidiary has received approval for the production of Ibuprofen granules, which are included in the national medical insurance drug list for 2025, suggesting a significant market opportunity in the pharmaceutical sector [1] Company Summary - The company, through its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Ibuprofen granules from the National Medical Products Administration [1] - The approval of Ibuprofen granules positions the company to capitalize on the growing demand for this medication in the Chinese market [1] Industry Summary - Ibuprofen granules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List for 2025 [1] - The estimated sales revenue for Ibuprofen-related formulations in Chinese public medical institutions is approximately RMB 4.4 billion in 2024, indicating a substantial market size and potential for growth [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its ibuprofen granules, indicating a significant development in its product portfolio and potential market expansion [1] Group 1: Company Announcement - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has been granted a drug registration certificate for ibuprofen granules [1] - The approved product is intended for the relief of mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, dysmenorrhea, and fever caused by common colds or influenza [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Ibuprofen Granules from the National Medical Products Administration, indicating a significant advancement in its product portfolio and potential market impact [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has successfully obtained the drug registration certificate for Ibuprofen Granules [1] - The registration application for Ibuprofen Granules was submitted to the Center for Drug Evaluation (CDE) in December 2023 and was accepted, leading to the approval in March 2026 [1] Group 2: Product Information - Ibuprofen Granules are indicated for the relief of mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, as well as for fever caused by common colds or influenza [1] - The product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 edition) [1] Group 3: Market Insights - The sales revenue for ibuprofen-related formulations in Chinese public medical institutions is projected to be approximately RMB 4.4 billion in 2024 [1]